Table 3 Response outcomes (n = 52).

From: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Outcomes

Patients

Overall objective response, n (%) [95% CI]

22 (42.3)

[28.9–55.7]

Complete response, n (%)

3 (5.8)

Partial response, n (%)

19 (36.5)

Stable disease, n (%)

10 (19.2)

Progressive disease, n (%)

16 (30.8)

Patients who had missing data or could not be evaluated, n (%)

4 (7.7)

Median duration of response (95% CI); months

12.7 [4.1–21.4]

Median cycle to best response (95% CI); months

3.0 (1–7)

Back to article page